Cancer treatment reviews最新文献

{"title":"Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm","authors":"Umair Mahmood ,&nbsp;Ewa Carrier ,&nbsp;Khurum Khan","doi":"10.1016/j.ctrv.2024.102750","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102750","url":null,"abstract":"<div><p>Traditional chemotherapy-based adjuvant therapies for locally advanced pancreatic ductal adenocarcinoma (PDAC) have been associated with poor clinical outcomes driven partly by its complex anatomy and molecular heterogeneity. Treatment for PDAC is challenged by presence of a dense tumour microenvironment involving an interplay of multiple tumoural and stromal components which promote metastatic oncogenic behaviour. PDAC also involves aberrations in multiple signalling pathways with paucity of treatment options against the most common mutations including <em>KRAS, TP53, CDKN2A</em> and<!--> <em>SMAD4</em>. However, recent discovery of new mechanisms implicated in pancreatic carcinogenesis have led to identification of promising mechanistic therapeutic targets such as <em>NET1</em> and <em>ULK1</em>. Early evidence also suggests the utility of targeting multiple DNA repair processes, modulators of DNA replication and major DNA damage response regulators. We explore the clinical rationale behind a neoadjuvant therapeutic strategy and emerging predictors of survival benefit associated with this approach. We also discuss challenges and opportunities originating from recent clinical trials evaluating neoadjuvant treatments composed of various combinations of radiotherapy, chemotherapy and immunotherapeutic regimens that have aimed to address some of these biological challenges. Selective treatment of patients harbouring specific genomic aberrations with targeted agents and immunotherapy can translate into optimum survival outcomes in PDAC. We also share perspectives on emerging prospective clinical evidence regarding stromal modifying agents, such as Tumour Growth Factor-Beta and Connective Tissue Growth Factor inhibitors along with novel vaccination-based approaches in improving PDAC outcomes.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102750"},"PeriodicalIF":11.8,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment","authors":"Sushree Subhadra Acharya,&nbsp;Chanakya Nath Kundu","doi":"10.1016/j.ctrv.2024.102749","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102749","url":null,"abstract":"<div><p>Cancer cells merely exist in isolation; rather, they exist in an intricate microenvironment composed of blood vessels, signalling molecules, immune cells, stroma, fibroblasts, and the ECM. The TME provides a setting that is favourable for the successful growth and survivance of tumors. Angiogenesis is a multifaceted process that is essential for the growth, invasion, and metastasis of tumors. TME can be visualized as a “concert hall,“ where various cellular and non-cellular factors perform in a “symphony” to orchestrate tumor angiogenesis and create “Havoc” instead of “Harmony”. In this review, we comprehensively summarized the involvement of TME in regulating tumor angiogenesis. Especially, we have focused on immune cells and their secreted factors, inflammatory cytokines and chemokines, and their role in altering the TME. We have also deciphered the crosstalk among various cell types that further aids the process of tumor angiogenesis. Additionally, we have highlighted the limitations of existing anti-angiogenic therapy and discussed various potential strategies that could be used to overcome these challenges and improve the efficacy of anti-angiogenic therapy.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102749"},"PeriodicalIF":11.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140842872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going","authors":"Miguel Muniz ,&nbsp;Charles L Loprinzi ,&nbsp;Jacob J Orme ,&nbsp;Regina M Koch ,&nbsp;Ahmed M Mahmoud ,&nbsp;Adam M Kase ,&nbsp;Irbaz B Riaz ,&nbsp;Jack R Andrews ,&nbsp;Matthew P Thorpe ,&nbsp;Geoffrey B Johnson ,&nbsp;Ayse T Kendi ,&nbsp;Eugene D Kwon ,&nbsp;Jones T Nauseef ,&nbsp;Alicia K Morgans ,&nbsp;Oliver Sartor ,&nbsp;Daniel S Childs","doi":"10.1016/j.ctrv.2024.102748","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102748","url":null,"abstract":"<div><p>Clinical trials of prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals have shown encouraging results. Some agents, like lutetium-177 [177Lu]Lu-PSMA-617 ([¹⁷⁷Lu]Lu-PSMA-617), are already approved for late line treatment of metastatic castration-resistant prostate cancer (mCRPC). Projections are for continued growth of this treatment modality; [¹⁷⁷Lu]Lu-PSMA-617 is being studied both in earlier stages of disease and in combination with other anti-cancer therapies. Further, the drug development pipeline is deep with variations of PSMA-targeting radionuclides, including higher energy alpha particles conjugated to PSMA-honing vectors. It is safe to assume that an increasing number of patients will be exposed to PSMA-targeted radiopharmaceuticals during the course of their cancer treatment. In this setting, it is important to better understand and mitigate the most commonly encountered toxicities. One particularly vexing side effect is xerostomia. In this review, we discuss the scope of the problem, inventories to better characterize and monitor this troublesome side effect, and approaches to preserve salivary function and effectively palliate symptoms. This article aims to serve as a useful reference for prescribers of PSMA-targeted radiopharmaceuticals, while also commenting on areas of missing data and opportunities for future research.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102748"},"PeriodicalIF":11.8,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials","authors":"Marcello Tucci ,&nbsp;Marta Mandarà ,&nbsp;Jacopo Giuliani ,&nbsp;Emilia Durante ,&nbsp;Consuelo Buttigliero ,&nbsp;Fabio Turco ,&nbsp;Erica Palesandro ,&nbsp;Ilaria Campisi ,&nbsp;Navdeep Singh ,&nbsp;Marco Muraro ,&nbsp;Fernando Munoz ,&nbsp;Francesco Fiorica","doi":"10.1016/j.ctrv.2024.102745","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102745","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><p> <!-->The average five-year survival of metastatic renal cell carcinoma (mRCC) is 71%. However, there is significant variability in patient prognosis. Immune checkpoint inhibitors (ICIs) have been introduced into the treatment landscape of mRCC. This <em>meta</em>-analysis aimed to estimate progression-free and overall survival probabilities and identify possible outcome predictors of mRCC patients treated with ICI combination as first-line treatment.</p></div><div><h3>Methods</h3><p> <!-->Studies comparing the combination of ICI combinations versus standard of therapy for first-line treatment of advanced renal-cell carcinoma were searched in MEDLINE, CANCERLIT, the Cochrane Controlled Trials Register, and the Cochrane Library from inception through September 2023. Data on patient populations and outcomes were extracted from each study by three independent observers and combined using the DerSimonian and Laird methods.</p></div><div><h3>Results</h3><p> <!-->Six studies met the inclusion criteria. Globally, 5121 patients were included in this <em>meta</em>-analysis: 2556 patients treated with immune checkpoint inhibitors and 2565 with sunitinib as control. The ICI combination was associated with improved PFS (hazard ratio (HR) 0.68; 95 % confidence interval (CI), 0.56–0.81, p &lt; 0.0001). Furthermore, ICI combination was also associated with OS improvement (HR 0.85; 95 % CI, 0.78–0.92, p = 0.001). There is no statistical increase in adverse events.</p></div><div><h3>Conclusions</h3><p> <!-->Our findings show that PFS and OS are statistically increased in mRCC with ICI combination treatment by 32% and 15%, respectively.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102745"},"PeriodicalIF":11.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140894921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agnostic drug development revisited","authors":"Alberto Hernando-Calvo ,&nbsp;Alice Rossi ,&nbsp;Maria Vieito ,&nbsp;Emile Voest ,&nbsp;Elena Garralda","doi":"10.1016/j.ctrv.2024.102747","DOIUrl":"10.1016/j.ctrv.2024.102747","url":null,"abstract":"<div><p>The advent of molecular profiling and the generalization of next generation sequencing in oncology has enabled the identification of patients who could benefit from targeted agents. Since the tumor-agnostic approval of pembrolizumab for patients with MSI-High tumors in 2017, different molecularly-guided therapeutics have been awarded approvals and progressively incorporated in the treatment landscape across multiple tumor types. As the number of tumor-agnostic targets considered druggable expands in the clinic, novel challenges will reshape the drug development field involving all the stakeholders in oncology. In this review, we provide an overview of current tumor-agnostic approvals and discuss promising candidate therapeutics for tumor-agnostic designation and challenges for their broad implementation.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"128 ","pages":"Article 102747"},"PeriodicalIF":11.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis” [Cancer Treat. Rev. 125 (2024) 102704]","authors":"K.R.J. Kistemaker ,&nbsp;F. Sijani ,&nbsp;D.J. Brinkman ,&nbsp;A. de Graeff ,&nbsp;G.L. Burchell ,&nbsp;M.A.H. Steegers ,&nbsp;L. van Zuylen","doi":"10.1016/j.ctrv.2024.102738","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102738","url":null,"abstract":"","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102738"},"PeriodicalIF":11.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000665/pdfft?md5=40774cc406deb9739598f28eb949855b&pid=1-s2.0-S0305737224000665-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140807159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives","authors":"Pablo Jiménez-Labaig ,&nbsp;Antonio Rullan ,&nbsp;Irene Braña ,&nbsp;Alberto Hernando-Calvo ,&nbsp;Victor Moreno ,&nbsp;Bernard Doger ,&nbsp;George Bitar ,&nbsp;Derfel Ap Dafydd ,&nbsp;Alan Melcher ,&nbsp;Kevin J. Harrington","doi":"10.1016/j.ctrv.2024.102746","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102746","url":null,"abstract":"<div><h3>Background</h3><p>Head and neck squamous cell carcinoma (HNSCC) presents an ideal scenario for intratumoral therapies (IT), due to its local recurrence pattern and frequent superficial extension. IT therapies aim to effect tumor regression by directly injecting antineoplastic agents into lesions. However, there is a lack of updated evidence regarding IT therapies in HNSCC.</p></div><div><h3>Patients and methods</h3><p>A systematic literature search (CRD42023462291) was conducted using WebOfScience, <span>ClinicalTrials.gov</span><svg><path></path></svg>, and conference abstracts from ESMO and ASCO, identifying for IT clinical trials in patients with HNSCC, from database creation to September 12th, 2023. Efficacy as well as safety (grade ≥ 3 treatment-related adverse events[trAEs]) were reported.</p></div><div><h3>Results</h3><p>After evaluation of 1180 articles identified by the systematic search, 31 studies treating 948 patients were included. IT injectables were categorized as chemotherapies with or without electroporation (k = 4, N = 268), oncolytic viruses, plasmids, and bacteria-based (k = 16, N = 446), immunotherapies and EGFR-based therapies (k = 5, N = 160), radioenhancer particles (k = 2, N = 68), and calcium electroporation (k = 1, n = 6). EGFR-antisense plasmids, NBTXR3 radioenhancer and immune innate agonists show best overall response rates, at 83 %, 81 % and 44 % respectively. Eleven (35 %) studies added systemic therapy or radiotherapy to the IT injections. No study used predictive biomarkers to guide patient selection. 97 % studies were phase I-II. Safety-wise, electroporation and epinephrine-based injectable trials had significant local symptoms such as necrosis, fistula formation and post-injection dysphagia. Treatment-related tumor haemorrhages of various grades were described in several trials. Grade ≥ 3 trAEs attributable to the other therapies mainly comprised general symptoms such as fatigue. There were 3 injectable-related deaths across the systematic review.</p></div><div><h3>Conclusion</h3><p>This is the first review to summarize all available evidence of IT in HNSCC. As of today, IT therapies lack sufficient evidence to recommend their use in clinical practice. Continuing research on potential molecules, patient selection, safe administration of injections and controlled randomized trials are needed to assess their added benefit.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102746"},"PeriodicalIF":11.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140816718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review","authors":"J. Bos ,&nbsp;T.S. Groen-van Schooten ,&nbsp;C.P. Brugman ,&nbsp;F.S. Jamaludin ,&nbsp;H.W.M. van Laarhoven ,&nbsp;S. Derks","doi":"10.1016/j.ctrv.2024.102737","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102737","url":null,"abstract":"<div><h3>Background</h3><p>Gastric cancer (GC), known for its unfavorable prognosis, has been classified in four distinct molecular subtypes. These subtypes not only exhibit differences in their genome and transcriptome but also in the composition of their tumor immune microenvironment. The microsatellite instable (MSI) and Epstein-Barr virus (EBV) positive GC subtypes show clear clinical benefits from immune checkpoint blockade, likely due to a neoantigen-driven and virus-driven antitumor immune response and high expression of immune checkpoint molecule PD-L1. However, even within these subtypes response to checkpoint inhibition is variable, which is potentially related to heterogeneity in the tumor immune microenvironment (TIME) and expression of co-inhibitory molecules. We conducted a systematic review to outline the current knowledge about the immunological features on the TIME of MSI and EBV + GCs.</p></div><div><h3>Methods</h3><p>A systematic search was performed in PubMed, EMBASE and Cochrane Library. All articles from the year 1990 and onwards addressing immune features of gastric adenocarcinoma were reviewed and included based on predefined in- and exclusion criteria.</p></div><div><h3>Results</h3><p>In total 5962 records were screened, of which 139 were included that reported immunological data on molecular GC subtypes. MSI and EBV + GCs were reported to have a more inflamed TIME compared to non-MSI and EBV- GC subtypes. Compared to microsatellite stable (MSS) tumors, MSI tumors were characterized by higher numbers of CD8 + and FoxP3 + T cells, and tumor infiltrating pro- and anti-inflammatory macrophages. HLA-deficiency was most common in MSI tumors compared to other molecular GC subtypes and associated with lower T and B cell infiltrates compared to HLA-proficient tumors. EBV + was associated with a high number of CD8 + T cells, Tregs, NK cells and macrophages. Expression of PD-L1, CTLA-4, Granzyme A and B, Perforin and interferon-gamma was enriched in EBV + tumors. Overall, MSI tumors harbored a more heterogeneous TIME in terms of immune cell composition and immune checkpoints compared to the EBV + tumors.</p></div><div><h3>Discussion and conclusion</h3><p>MSI and EBV + GCs are highly <em>Handbook for Conducting a Literature-Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration</em>.; 2019pro-inflammatory immune cell populations. Although studies on the direct comparison of EBV + and MSI tumors are limited, EBV + tumors show less intra-subgroup heterogeneity compared to MSI tumors. More studies are needed to identify how Intra-subgroup heterogeneity impacts response to immunotherapy efficacy.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102737"},"PeriodicalIF":11.8,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000641/pdfft?md5=cf5fafa8f781a9a9ae69668d279d64b7&pid=1-s2.0-S0305737224000641-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dutch national guidelines for locally recurrent rectal cancer","authors":"Floor Piqeur ,&nbsp;Davy M.J. Creemers ,&nbsp;Evi Banken ,&nbsp;Liën Coolen ,&nbsp;Pieter J. Tanis ,&nbsp;Monique Maas ,&nbsp;Mark Roef ,&nbsp;Corrie A.M. Marijnen ,&nbsp;Irene E.G. van Hellemond ,&nbsp;Joost Nederend ,&nbsp;Harm J.T. Rutten ,&nbsp;Heike M.U. Peulen ,&nbsp;Jacobus W.A. Burger","doi":"10.1016/j.ctrv.2024.102736","DOIUrl":"10.1016/j.ctrv.2024.102736","url":null,"abstract":"<div><p>Due to improvements in treatment for primary rectal cancer, the incidence of LRRC has decreased. However, 6–12% of patients will still develop a local recurrence. Treatment of patients with LRRC can be challenging, because of complex and heterogeneous disease presentation and scarce − often low-grade − data steering clinical decisions. Previous consensus guidelines have provided some direction regarding diagnosis and treatment, but no comprehensive guidelines encompassing all aspects of the clinical management of patients with LRRC are available to date. The treatment of LRRC requires a multidisciplinary approach and overarching expertise in all domains. This broad expertise is often limited to specific expert centres, with dedicated multidisciplinary teams treating LRRC. A comprehensive, narrative literature review was performed and used to develop the Dutch National Guideline for management of LRRC, in an attempt to guide decision making for clinicians, regarding the complete clinical pathway from diagnosis to surgery.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"127 ","pages":"Article 102736"},"PeriodicalIF":11.8,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140767871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials","authors":"V. Conca ,&nbsp;P. Ciracì ,&nbsp;C. Boccaccio ,&nbsp;A. Minelli ,&nbsp;C. Antoniotti ,&nbsp;C. Cremolini","doi":"10.1016/j.ctrv.2024.102735","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102735","url":null,"abstract":"<div><p>Since colon cancer has a high rate of shedding of tumour fragments into the blood, several research efforts are now focused on the investigation of the minimal residual disease through the detection of ctDNA to tailor the adjuvant therapy of colon cancer patients and optimize its cost/effectiveness balance. The negative prognostic impact of detectable ctDNA in patients’ blood after radical surgery for colon cancer is well established. Several clinical trials adopting heterogeneous designs and techniques are now ongoing to translate promises into daily practice by answering five general questions: i) is a ctDNA-guided decision making efficacious in the post-operative management of colon cancer patients? ii) are de-escalation strategies possible in ctDNA-negative cases? iii) are escalation strategies useful to improve the prognosis of ctDNA-positive patients? iv) when MRD is identified at the end of the adjuvant chemotherapy, is another post-adjuvant systemic therapy efficacious? v) can we exploit ctDNA technologies in the follow up of colon cancer patients? This review focuses on currently ongoing trials and how their results may affect the ctDNA “liquid revolution” of early colon cancer.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"126 ","pages":"Article 102735"},"PeriodicalIF":11.8,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000628/pdfft?md5=37a7d95e19d22d96c7c457ba7b40bab5&pid=1-s2.0-S0305737224000628-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140547119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}